4 research outputs found
Short-term changes in klotho and FGF23 in heart failure with reduced ejection fractionâa substudy of the DAPA-VO2 study
The klotho and fibroblast growth factor 23 (FGF-23) pathway is implicated in cardiovascular pathophysiology. This substudy aimed to assess the changes in klotho and FGF-23 levels 1-month after dapagliflozin in patients with stable heart failure and reduced ejection fraction (HFrEF). The study included 29 patients (32.2% of the total), with 14 assigned to the placebo group and 15 to the dapagliflozin, as part of the double-blind, randomized clinical trial [DAPA-VO2 (NCT04197635)]. Blood samples were collected at baseline and after 30 days, and Klotho and FGF-23 levels were measured using ELISA Kits. Between-treatment changes (raw data) were analyzed by using the Mann-Whitney test and expressed as median (p25%âp75%). Linear regression models were utilized to analyze changes in the logarithm (log) of klotho and FGF-23. The median age was 68.3 years (60.8â72.1), with 79.3% male and 81.5% classified as NYHA II. The baseline medians of left ventricular ejection fraction, glomerular filtration rate, NT-proBNP, klotho, and FGF-23 were 35.8% (30.5â37.8), 67.4â
ml/min/1.73â
m2 (50.7â82.8), 1,285â
pg/ml (898â2,305), 623.4â
pg/ml (533.5â736.6), and 72.6â
RU/ml (62.6â96.1), respectively. The baseline mean peak oxygen uptake was 13.1â±â4.0â
ml/kg/min. Compared to placebo, patients on dapagliflozin showed a significant median increase of klotho [Î+29.5, (12.9â37.2); pâ=â0.009] and a non-significant decrease of FGF-23 [Îâ4.6, (â1.7 to â5.4); pâ=â0.051]. A significant increase in log-klotho (pâ=â0.011) and a decrease in log-FGF-23 (pâ=â0.040) were found in the inferential analysis. In conclusion, in patients with stable HFrEF, dapagliflozin led to a short-term increase in klotho and a decrease in FGF-23
Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients
Tatton-Brown-Rahman (TBRS) syndrome is a recently described overgrowth syndrome caused by loss of function variants in the DNMT3A gene. This gene encodes for a DNA methyltransferase 3 alpha, which is involved in epigenetic regulation, especially during embryonic development. Somatic variants in DNMT3A have been widely studied in different types of tumors, including acute myeloid leukemia, hematopoietic, and lymphoid cancers. Germline gain-of-function variants in this gene have been recently implicated in microcephalic dwarfism. Common clinical features of patients with TBRS include tall stature, macrocephaly, intellectual disability (ID), and a distinctive facial appearance. Differential diagnosis of TBRS comprises Sotos, Weaver, and Malan Syndromes. The majority of these disorders present other clinical features with a high clinical overlap, making necessary a molecular confirmation of the clinical diagnosis. We here describe seven new patients with variants in DNMT3A, four of them with neuropsychiatric disorders, including schizophrenia and psychotic behavior. In addition, one of the patients has developed a brain tumor in adulthood. This patient has also cerebral atrophy, aggressive behavior, ID, and abnormal facial features. Clinical evaluation of this group of patients should include a complete neuropsychiatric assessment together with psychological support in order to detect and manage abnormal behaviors such as aggressiveness, impulsivity, and attention deficit-hyperactivity disorder. TBRS should be suspected in patients with overgrowth, ID, tall stature, and macrocephaly, who also have some neuropsychiatric disorders without any genetic defects in the commonest overgrowth disorders. Molecular confirmation in these patients is mandatory.This project was supported by ISCII, FEDER funds grant: FIS-PI15/01481
Microrelatario
Multitud d'autores i autors aporten pĂndoles de microliteratura, de gĂšneres diversos, al segon volum amb quĂš l'Institut Universitari d'Estudis Feministes i de GĂšnere PurificaciĂłn Escribano vol respondre al desafiament per l'eradicaciĂł de la violĂšncia contra les dones